Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
InterVenn Biosciences logo — We are a life science company decoding the glycoproteome to...

InterVenn Biosciences

We are a life science company decoding the glycoproteome to power personalized, predictive, and preventive care.

Founded 2017 United States South San Francisco, United States 39 employees Series C Total: $278.09M AI, Biotechnology +2

General Information

Company Name InterVenn Biosciences
Founded Year 2017
Location United States South San Francisco, United States
Employees 39
Industries AI, Biotechnology, Health Care +1
Funding Stage Series C
Business Model B2B, Platform, SaaS
Revenue Model Service Fee, Licensing, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with InterVenn Biosciences. To contact InterVenn Biosciences, visit intervenn.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About InterVenn Biosciences

InterVenn Biosciences, founded in 2017, is a pioneering player in the AI, Biotechnology, Health Care, and Life Sciences industries, headquartered in the United States. The company's slogan, "We are a life science company decoding the glycoproteome to power personalized, predictive, and preventive care," encapsulates its mission to leverage advanced glycoproteomics for enhanced healthcare outcomes.

Co-founded by a team of distinguished experts including Nobel Laureate Dr. Carolyn Bertozzi, Dr. Carlito Lebrilla, and AI/ML specialist Aldo Carrascoso, InterVenn Biosciences has developed the proprietary platform GlycoVision™. This AI-driven technology is designed to offer clinical applications ranging from early disease detection to novel diagnostic and therapeutic solutions.

In its latest Series C funding round, the company raised $201.00M on August 2, 2021 with contributions from notable investors such as Amplify Partners, Anzu Partners, True Ventures, Genoa Ventures, SoftBank Capital, Heritage Provider Network, Highside Capital Management, and Irving Investors. This solidifies InterVenn's potential as a transformative force in precision medicine.

Taxonomy: glycoproteome, personalized healthcare, predictive medicine, preventive care, GlycoVision platform, biomarker discovery, early disease screening, diagnostics, therapeutics development, AI-powered platform, biological insights, pharma partnerships, protein glycosylation, mass spectrometry

Services & Products

Glycoproteomic Diagnostics
Biomarker Discovery
Therapeutic Response Monitoring
Glycopeptide Quantification

Target Customers

Medical Researchers Oncologists Biotechnology Companies Healthcare Institutions

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $201.00M 8
Amplify Partners Anzu Partners True Ventures
Amplify Partners, Anzu Partners +6
02 Aug 2021
Series B $34.00M 2
Genoa Ventures
Genoa Ventures, Ojjeh Family Fund
16 Nov 2020
Venture Round $33.69M -
13 Jul 2020
Venture Round $9.40M -
12 Dec 2018
Seed Round Undisclosed -
01 Apr 2017

InterVenn Biosciences Alternatives & Competitors

View All Alternatives
InterVenn Biosciences vs
Olaris, Inc
Olaris, Inc United States

Removing the Guesswork from Medicine

Series B
16 employees
Biopharma, Biotechnology
InterVenn Biosciences vs
Scailyte
Scailyte Switzerland

True precision medicine through single-cell science.

Series A
18 employees
AI, Biotechnology
InterVenn Biosciences vs
Moonwalk Biosciences
Moonwalk Biosciences United States

Pioneering novel therapeutics in adipose biology and tissue, driven by deep genetic and epigenetic i...

Series A
21 employees
AI, Biopharma
Also compare with: InterVenn Biosciences vs SomaScan SomaScan View all alternatives

FAQ About InterVenn Biosciences

We are a life science company decoding the glycoproteome to power personalized, predictive, and preventive care.
InterVenn Biosciences was founded in 2017.
InterVenn Biosciences is headquartered in South San Francisco, United States.
InterVenn Biosciences operates in AI, Biotechnology, Health Care and Life Sciences. Its work centres on glycoproteome, personalized healthcare, predictive medicine and preventive care. Its customers include Medical Researchers, Oncologists and Biotechnology Companies.
InterVenn Biosciences has a B2B, Platform and SaaS business model. Its revenue comes from Service Fee, Licensing and Data Monetization.
InterVenn Biosciences has approximately 39 employees.
InterVenn Biosciences has completed 5 funding rounds, raising a total of $278.09M. The latest funding stage is Series C.
InterVenn Biosciences offers: Glycoproteomic Diagnostics, Biomarker Discovery, Therapeutic Response Monitoring, Glycopeptide Quantification.
Top alternatives and competitors to InterVenn Biosciences include Olaris, Inc, Scailyte, Moonwalk Biosciences, OmicEra Diagnostics, NanoMosaic Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InterVenn Biosciences and Olaris, Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for InterVenn Biosciences, https://bouncewatch.com/company/intervenn-biosciences, updated 15 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes